Company intelligence / Profile preview

Candel Therapeutics

Needham, Massachusetts, United Statescandeltx.com ↗

Ownership: Public · CADL
Employees: ~100
Development stage: Phase 3

Overview

Candel has completed Phase 3 clinical trials for CAN-2409 in prostate cancer with positive results to be presented at ASCO 2025. Phase 2a trials for pancreatic cancer showed median overall survival of 28.8 months versus 12.5 months in the control group. The company has approximately $103M in cash as of December 2024, expected to fund operations into Q1 2027.

Therapeutic areas: Oncology
Modalities: Viral immunotherapiesOncolytic viral immunotherapyMultimodal biological immunotherapies
Industry: Biotech

Drug pipeline

7 assets

adenovirus-thymidine kinase

Approved

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $830.2M
Total revenue: $0
Enterprise value: $678.1M

Beyond the preview

Go deeper on Candel Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Candel Therapeutics.

Explore the full profile